{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:40:58Z","timestamp":1789612858204,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.bmc.2005.01.005","type":"journal-article","created":{"date-parts":[[2005,2,10]],"date-time":"2005-02-10T23:36:33Z","timestamp":1108078593000},"page":"2065-2077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family"],"prefix":"10.1016","volume":"13","author":[{"given":"Antonello","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Artico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Ragno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Sbardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Musiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Marturana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Maga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo La","family":"Colla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2005.01.005_bib1","first-page":"305","article-title":"Nonnucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials","volume":"51","author":"Artico","year":"1995","journal-title":"Farmaco"},{"key":"10.1016\/j.bmc.2005.01.005_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1135\/cccc19980449","article-title":"New perspectives for the treatment of HIV infections","volume":"63","author":"De Clercq","year":"1998","journal-title":"Collect. Czech. Chem. Commun."},{"key":"10.1016\/j.bmc.2005.01.005_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-3542(98)00025-4","article-title":"The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection","volume":"38","author":"De Clercq","year":"1998","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bmc.2005.01.005_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/095632029901000601","article-title":"Nonnucleoside reverse transcriptase inhibitors: the NNRTI boom","volume":"10","author":"Pedersen","year":"1999","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1126\/science.1701568","article-title":"Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor","volume":"250","author":"Merluzzi","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bmc.2005.01.005_bib6","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm9707030","article-title":"Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones","volume":"41","author":"Cywin","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/jm00033a018","article-title":"Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"37","author":"Romero","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib8","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1021\/jm990051a","article-title":"Synthesis and structure\u2013activity relationships of the (alkylamino)piperidine-containing BHAP class of non-nucleoside reverse transcriptase inhibitors: effect of 3-alkylpyridine ring substitution","volume":"42","author":"Genin","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib9","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1128\/jvi.65.9.4887-4892.1991","article-title":"Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors","volume":"65","author":"Nunberg","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.bmc.2005.01.005_bib10","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.42.12.3123","article-title":"Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride","volume":"42","author":"Miller","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2174\/1381612024607207","article-title":"Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives","volume":"8","author":"Campiani","year":"2002","journal-title":"Curr. Pharm. Design"},{"key":"10.1016\/j.bmc.2005.01.005_bib12","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1128\/AAC.39.12.2602","article-title":"L-743,726 (DMP-266): a novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase","volume":"39","author":"Young","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/AAC.42.6.1340","article-title":"S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1","volume":"42","author":"Fujiwara","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.38.4.688","article-title":"Preclinical evaluation of MKC-442. A highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro","volume":"38","author":"Baba","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/jm960056x","article-title":"Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors","volume":"39","author":"Hopkins","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dof.2002.027.02.653978","article-title":"Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABOs family","volume":"27","author":"Artico","year":"2002","journal-title":"Drug Fut."},{"key":"10.1016\/j.bmc.2005.01.005_bib17","first-page":"65","article-title":"3,4-Dihydro-2-alkoxy-6-benzyl-oxopyrimidines (DABOs): development of a potent class of non-nucleoside reverse transcriptase inhibitors","volume":"1","author":"Marongiu","year":"2002","journal-title":"Recent Res. Develop. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib18","unstructured":"Marongiu, M. E.; Pani, A.; Artico, M.; Massa, S.; Mai, A.; La Colla, P. Selective inhibition of HIV-1 replication by a novel series of 2-substituted 6-benzyl-pyrimidines. VIII International Conference on AIDS. 1992, Amsterdam July 19\u201324, PoA 2315"},{"key":"10.1016\/j.bmc.2005.01.005_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/095632029300400608","article-title":"3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1","volume":"4","author":"Artico","year":"1993","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib20","first-page":"269","article-title":"Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Tramontano","year":"1994","journal-title":"Microbiologica"},{"key":"10.1016\/j.bmc.2005.01.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632029500600101","article-title":"Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus Type-1","volume":"6","author":"Massa","year":"1995","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.bmc.2005.01.005_bib22","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1021\/jm00017a010","article-title":"Synthesis and anti-HIV-1 activity of thio analogs of dihydroalkoxybenzyloxopyrimidines","volume":"38","author":"Mai","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib23","first-page":"2115","article-title":"6-(3-Methylbenzyl)-2-(2-methylpropyl)thio-4(3H)-pyrimidinone (DABO 622)","volume":"C52","author":"Ettorre","year":"1995","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.bmc.2005.01.005_bib24","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1021\/jm960802y","article-title":"Dihydro(alkylthio)(naphthylmethyl) oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series","volume":"40","author":"Mai","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/jm980260f","article-title":"5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives","volume":"42","author":"Mai","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib26","first-page":"30","article-title":"Does the 2-methylthiomethyl substituent really confer high anti-HIV-1 activity to S-DABOs?","volume":"10","author":"Artico","year":"2000","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bmc.2005.01.005_bib27","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/jm010853h","article-title":"Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase","volume":"44","author":"Mai","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/jm0309856","volume":"47","author":"Ragno","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1006\/jmbi.2001.4988","article-title":"Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors","volume":"312","author":"Ren","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bmc.2005.01.005_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0166-0934(88)90134-6","article-title":"Rapid and automated tetrazolium-based assay for the detection of anti-HIV compounds","volume":"20","author":"Pauwels","year":"1988","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.bmc.2005.01.005_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0006-2952(92)90515-K","article-title":"HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587","volume":"43","author":"Tramontano","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bmc.2005.01.005_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jcc.540110405","article-title":"MacroModel\u2014An integrated software system for modeling organic and bioorganic molecules using molecular mechanics","volume":"11","author":"Mohamadi","year":"1990","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6","article-title":"Automated docking of flexible ligands: applications of AutoDock","volume":"9","author":"Goodsell","year":"1995","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.bmc.2005.01.005_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-4655(95)00041-D","article-title":"AMBER, a package of computer programs for applying molecular mechanics, normal-mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules","volume":"91","author":"Pearlman","year":"1995","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.bmc.2005.01.005_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bmc.2005.01.005_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1520-636X(2001)13:2<75::AID-CHIR1001>3.0.CO;2-W","article-title":"Chiral resolution and molecular modeling investigation of rac-2-cyclopentylthio-6-[1-(2,6-difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a potent anti-HIV-1 reverse transcriptase agent of the DABO class","volume":"13","author":"Quaglia","year":"2001","journal-title":"Chirality"},{"key":"10.1016\/j.bmc.2005.01.005_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/10629360310001624033","article-title":"Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking","volume":"14","author":"Chen","year":"2003","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bmc.2005.01.005_bib38","unstructured":"Zhigang, Z.; Madura, J. Use of dock and PB in reproducing the binding mode and predicting the binding-free energies of non-nucleoside inhibitors to HIV-1 reverse transcriptase. Presented at the 224th ACS National Meeting, Boston, MA, August 18\u201322, 2002, COMP-170"},{"key":"10.1016\/j.bmc.2005.01.005_bib39","first-page":"153","article-title":"Arylthiopyridylmethylisopropylpyrrole carbinols, novel NNRTIs endowed with potent anti-HIV-1 activity","volume":"11","author":"Di Santo","year":"2002","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bmc.2005.01.005_bib40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/jm0341913","article-title":"Discovery of a novel binding trench in HIV integrase","volume":"47","author":"Schames","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2005.01.005_bib41","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/ja001152x","article-title":"HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing","volume":"122","author":"Sotriffer","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bmc.2005.01.005_bib42","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1021\/ci034052u","article-title":"A comprehensive docking study on the selectivity of binding of aromatic compounds to proteins","volume":"43","author":"Hetenyi","year":"2003","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.bmc.2005.01.005_bib43","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","article-title":"The process of structure-based drug design","volume":"10","author":"Anderson","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bmc.2005.01.005_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0959-440X(03)00075-7","article-title":"Ligand binding: functional site location, similarity and docking","volume":"13","author":"Campbell","year":"2003","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bmc.2005.01.005_bib45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jmgm.2003.11.002","article-title":"A practical approach to docking of zinc metalloproteinase inhibitors","volume":"22","author":"Hu","year":"2004","journal-title":"J. Mol. Graph. Model"},{"key":"10.1016\/j.bmc.2005.01.005_bib46","first-page":"57","article-title":"Python: A programming language for software integration and development","volume":"17","author":"Michel","year":"1999","journal-title":"J. Mol. Graph. Mod."}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089605000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089605000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:50:12Z","timestamp":1760827812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089605000131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0968089605000131"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2005.01.005","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2005.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}